Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 12 points (0.1%) at 17,830 as of Tuesday, Nov. 25, 2014, 12:15 PM ET. The NYSE advances/declines ratio sits at 1,420 issues advancing vs. 1,510 declining with 216 unchanged. The Drugs industry currently sits down 0.2% versus the S&P 500, which is unchanged. On the negative front, top decliners within the industry include Receptos ( RCPT), down 5.2%, Incyte ( INCY), down 2.1%, Pharmacyclics ( PCYC), down 2.0%, Alexion Pharmaceuticals ( ALXN), down 0.8% and AstraZeneca ( AZN), down 0.3%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Vertex Pharmaceuticals ( VRTX) is one of the companies pushing the Drugs industry higher today. As of noon trading, Vertex Pharmaceuticals is up $0.46 (0.4%) to $114.26 on light volume. Thus far, 433,540 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $113.63-$114.99 after having opened the day at $114.17 as compared to the previous trading day's close of $113.80. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. Vertex Pharmaceuticals has a market cap of $26.8 billion and is part of the health care sector. Shares are up 49.9% year-to-date as of the close of trading on Monday. Currently there are 9 analysts who rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold. TheStreet Ratings rates Vertex Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, unimpressive growth in net income and disappointing return on equity. Get the full Vertex Pharmaceuticals Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.